Haemonetics Has Agreed To Acquire Opsens For C$2.90 Per Share In An All-cash Transaction Representing A Fully Diluted Equity Value Of Approximately $253M At The Current Exchange Rate
Portfolio Pulse from Benzinga Newsdesk
Haemonetics has agreed to acquire Opsens for C$2.90 per share in an all-cash transaction, representing a fully diluted equity value of approximately $253M at the current exchange rate.
October 10, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics is acquiring Opsens, which could potentially expand its product portfolio and market reach.
Acquisitions often provide companies with opportunities for growth, expansion into new markets, and increased product offerings. This acquisition could potentially benefit Haemonetics in these ways, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Opsens is being acquired by Haemonetics for C$2.90 per share, representing a fully diluted equity value of approximately $253M.
Acquisitions often result in a boost in the stock price of the company being acquired, as the purchase price usually represents a premium over the current market price. In this case, Opsens' stock price could potentially see a positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100